drugset / Trial / NCT01526850

Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease

NCT01526850

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of the study is to evaluate the safety and efficacy of mesenchymal stem cells (MSC) for the treatment of patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to first-line therapy. The secondary purpose of the study is to evaluate the effect of mesenchymal stem cells (MSC) on one-year survival rate, long-term survival rate, life quality and recurrence of patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to hormone treatment.

Timeline

Start
2012-02
Primary completion
2013-12
Completion
2014-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide
Subject Mesenchymal stem cell Cell therapy 1e+07 cells Other
Subject Mesenchymal stem cell Cell therapy 2e+07 cells Other